Incruse Ellipta

GlaxoSmithKline LLC🇺🇸 United States

FDA Page

Effective Date: Dec 13, 2023
Approval ID: dbb64747-1505-49d7-9a33-99dd402e96d3
Products: 1 registered
Version: 27

Regulatory Information

Labeling Type

HUMAN PRESCRIPTION DRUG LABEL

Status

Approved

Full Title

These highlights do not include all the information needed to use INCRUSE ELLIPTA safely and effectively. See full prescribing information for INCRUSE ELLIPTA.INCRUSE ELLIPTA (umeclidinium inhalation powder), for oral inhalation useInitial U.S. Approval: 2013

Quick Stats

Total Products1

Labelers2

Label Sections36

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.